The Experts – REVIVE

About
The Experts
Webinars
- External webinars
Resources
Forums
Talk to an expert
JOIN US
My account
- Logout

Loading...

The Experts

Our team of experts (more coming soon)

You are here:Home-The Experts

Antoine Andremont — Antoine Andremont
Emeritus Professor
Paris Diderot University Medical School

Jesús Rodríguez-Baño — Jesús Rodríguez-Baño
Professor of Medicine
University of Seville

Michael Barbachyn — Michael Barbachyn
Professor, Brummel Chair in Organic Chemistry
Calvin College

Greg Basarab — Greg Basarab
Principal Research Officer and Associate Director
University of Cape Town

Alex van Belkum — Alex van Belkum
Scientific Director, Microbiology R&D
bioMérieux

Helen W Boucher — Helen W Boucher
Professor of Medicine, Director, Infectious Disease Fellowship Program
Tufts Medical Center

Pamela Brown — Pamela Brown
Consultant
Antibacterial Drug Discovery and Medicinal Chemistry

Karen Bush — Karen Bush
Professor of Practice
Department of Biology, Indiana University

Vincent Cattoir — Vincent Cattoir
Professor of Clinical Microbiology
University of Rennes

Ryan Cirz — Ryan Cirz
Vice president, Infectious Disease Research and Head, Postdoctoral Program
Achaogen

Matthew Cooper — Matthew Cooper
Chief Executive Officer
Inflazome

Patrice Courvalin — Patrice Courvalin
Emeritus Professor
Department of Microbiology, Institut Pasteur

1
2
3
…
5
Next »

Share

Facebook Twitter Linkedin Reddit Email

REVIVE Hub

REVIVE is a space for everybody with an interest in antimicrobial R&D.

Launched in 2016 by the WHO and DNDi, the Global Antibiotic Research & Development Partnership (GARDP) aims to develop and deliver new treatments for bacterial infections where drug resistance is present or emerging, or for which inadequate treatment exists, while endeavouring to ensure sustainable access. GARDP is currently operating within DNDi, which provides its governance.

Popular forum topics

Setting Up A 'Support' Service in Anti-Infectives
Superiority vs. non-inferiority studies – can PK-PD bridge this gap?
Immunomodulators
Medical need and priorities

Latest forum posts

Medicare’s New Technology Add-on Payment (NTAP) program
Lung or thigh infection models for UTI/ABSSI indication
Route of administration for treatment vs. that for determining PK
MIC50 or MIC90 in PD calculations?

CONNECT

Facebook
Twitter
Instagram
LinkedIn
YouTube
RSS
Events

GARDP
DNDi

© All Rights Reserved

Privacy Policy | Terms of Use | Acceptable Use Policy | Cookie Policy

We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser.
Read our cookie policy